Report Overview
The Microbiome-Oncology market is projected to grow at a CAGR of 40.7% over the forecast period, increasing from USD 353.20 million in 2026 to USD 1,945.22 million by 2031.
The market is defined by the interaction between microbiota composition and cancer progression. Demand is increasing as oncology outcomes are showing dependency on immune modulation influenced by microbial diversity. Therapeutic dependency remains on immunotherapy, which positions microbiome interventions as adjunct rather than primary treatments. Regulatory frameworks are evolving to classify live biotherapeutic products, which creates uncertainty in approval pathways. Companies are aligning development strategies with immunotherapy combinations to validate clinical relevance. Strategic importance is increasing as healthcare systems recognize microbiome modulation as a lever to improve treatment efficacy.
Market Dynamics
Market Drivers
Microbiome Influence on Immunotherapy Response: Immunotherapy effectiveness depends on immune system activation. Demand is increasing as microbiome composition is influencing checkpoint inhibitor outcomes. Variability in patient microbiota limits predictability of response. Companies are developing microbiome-based adjuncts to standard therapies. The market is expanding as microbiome modulation is improving immunotherapy efficacy.
Rising Immunotherapy Adoption Across Oncology: Immunotherapy defines modern cancer treatment frameworks. Adoption is increasing as checkpoint inhibitors are becoming standard of care. High costs constrain accessibility in emerging markets. Pharmaceutical companies are expanding indications to increase patient coverage. The market is growing as immunotherapy demand is expanding globally.
Expansion of Precision Medicine Approaches: Precision medicine relies on patient-specific biological markers. Demand is increasing as microbiome profiling is emerging as a predictive biomarker. Limited standardization restricts widespread adoption. Diagnostic companies are improving microbiome sequencing capabilities. The market is evolving as personalized treatment strategies are incorporating microbiome data.
Increasing Focus on Treatment Resistance Mechanisms: Treatment resistance limits long-term cancer outcomes. Demand is increasing as microbiome modulation is being explored to overcome resistance. Clinical validation remains incomplete, which slows adoption. Companies are conducting combination trials to validate efficacy. The market is advancing as resistance-driven innovation is expanding therapeutic options.
Market Restraints
Regulatory ambiguity around live biotherapeutic classification limits approval pathways
Lack of standardized microbiome profiling reduces clinical adoption
Limited large-scale clinical validation restricts physician confidence
Market Opportunities
Development of Live Biotherapeutic Products: Live biotherapeutics represent a new therapeutic class. Demand is increasing as microbial consortia are being engineered for immune modulation. Manufacturing complexity constrains scalability. Companies are investing in production capabilities to ensure consistency. The market is opening new treatment pathways as biologic innovation expands.
Integration with Checkpoint Inhibitors: Checkpoint inhibitors remain the foundation of immunotherapy. Demand is increasing as microbiome therapies are being combined to enhance efficacy. Combination toxicity remains a concern. Clinical trials are optimizing dosing strategies to manage safety. The market is shifting toward combination-based oncology treatment models.
Microbiome-Based Biomarker Development: Biomarkers guide treatment decisions in oncology. Demand is increasing as microbiome signatures are being explored as predictive indicators. Data variability constrains clinical reliability. Research institutions are standardizing analytical methods. The market is becoming more data-driven as biomarker integration improves treatment selection.
Supply Chain Analysis
The microbiome-oncology supply chain depends on biologic manufacturing and microbial culture processes. Demand is increasing as live biotherapeutics are advancing through clinical pipelines. Production consistency remains a constraint due to variability in microbial strains. Companies are investing in controlled manufacturing environments to ensure reproducibility. Distribution requires cold-chain logistics, which adds complexity to supply networks. The supply chain is evolving as biologics infrastructure expands to support microbiome therapies.
Government Regulations
Region | Regulatory Authority | Key Role |
United States | FDA | Oversight of live biotherapeutic products and oncology drugs |
Europe | EMA | Regulation of biologics and advanced therapies |
Japan | PMDA | Approval and monitoring of biologics |
India | CDSCO | Regulation of biologics and clinical trials |
China | NMPA | Approval of microbiome and oncology therapeutics |
Market Segmentation
By Therapy Type
Therapy type segmentation reflects treatment integration across oncology frameworks. Microbiome-based therapeutics are gaining relevance as adjunct therapies to immunotherapy. Immunotherapy demand is increasing due to its central role in cancer treatment. Chemotherapy usage remains stable but is declining relative to newer therapies. Targeted therapy adoption continues due to molecular specificity. The segment is evolving as microbiome therapies are integrating into established treatment pathways.
By Drug Class
Drug class segmentation highlights mechanistic diversity. Live biotherapeutic products are emerging as a novel class targeting microbiome modulation. Immune checkpoint inhibitors dominate due to established clinical efficacy. Microbiome modulators are being developed to influence immune response indirectly. FMT-based therapies are gaining attention in early-stage research. The segment is expanding as microbiome-specific drug classes are entering clinical development.
By Indication
Indication segmentation captures disease-specific demand. Colorectal cancer shows strong association with microbiome imbalance, which drives research focus. Melanoma demand is increasing due to immunotherapy reliance. Lung cancer adoption is expanding as microbiome influence is being explored. Renal and liver cancers are emerging as target areas. The segment is growing as microbiome relevance expands across multiple cancer types.
Regional Analysis
North America Market Analysis
The North American market is defined by strong clinical research infrastructure and early adoption of novel therapies. Demand is increasing as microbiome-oncology trials are expanding across major cancer centers. Regulatory clarity is improving through FDA guidance on live biotherapeutics. High treatment costs remain a constraint, which limits accessibility. Companies are investing heavily in clinical trials to establish efficacy. The market is leading global adoption as innovation and funding support rapid development.
Europe Market Analysis
The European market operates under structured regulatory frameworks for biologics. Demand is increasing as research institutions are advancing microbiome studies. Regulatory processes remain complex, which delays approvals. Companies are collaborating with academic institutions to accelerate development. Healthcare systems are supporting innovation through funding programs. The market is progressing steadily as regulatory alignment supports microbiome research.
Asia Pacific Market Analysis
The Asia Pacific market is expanding due to increasing cancer burden and growing research capabilities. Demand is increasing as awareness of microbiome influence on health is rising. Infrastructure limitations constrain large-scale clinical trials. Governments are investing in biotechnology to support innovation. Companies are forming partnerships to expand regional presence. The market is accelerating as healthcare investment supports microbiome research.
Rest of the World
The Rest of the World market reflects emerging healthcare systems with limited microbiome research infrastructure. Demand is increasing as cancer incidence rises globally. Access to advanced therapies remains constrained due to cost and infrastructure gaps. Governments are improving healthcare access gradually. Companies are targeting these regions through partnerships. The market is developing as awareness and access improve.
Regulatory Landscape
Regulatory frameworks are evolving to accommodate microbiome-based therapies. The FDA is defining pathways for live biotherapeutic products, which provides clarity for developers. Approval processes remain stringent to ensure safety. EMA is aligning biologics regulation with advanced therapy guidelines. Regulatory harmonization remains limited, which creates regional variation. The regulatory environment is adapting as microbiome therapies move toward commercialization.
Clinical trial regulations are supporting innovation through adaptive trial designs. Demand is increasing as microbiome trials are expanding globally. Patient recruitment remains challenging due to niche indications. Regulatory agencies are facilitating trial approvals to accelerate development. The system is evolving as microbiome research gains importance in oncology.
Pipeline Analysis
The pipeline is dominated by early-stage microbiome therapeutics targeting immune modulation. Demand is increasing as companies are exploring microbiome-based approaches to enhance immunotherapy response. Clinical validation remains limited, which increases development risk. Companies are focusing on combination trials to improve outcomes. The pipeline is expanding as microbiome science advances.
Late-stage trials are limited, which constrains near-term commercialization. Demand is increasing for therapies addressing treatment resistance. Companies are prioritizing scalable manufacturing processes. Clinical success remains uncertain due to biological variability. The pipeline is evolving as research translates into clinical development.
Competitive Landscape
Seres Therapeutics, Inc.
The company establishes credibility through FDA-approved microbiome therapy. Demand is increasing as SER-109 demonstrates clinical viability of microbiome interventions. Oncology applications remain in development, which limits immediate revenue expansion. The company is advancing oncology trials to expand indications. The company is positioned as a pioneer in microbiome therapeutics.
Ferring Pharmaceuticals
The company validates fecal microbiota therapies through RBX2660 approval. Demand is increasing as microbiome therapies gain regulatory acceptance. Oncology applications remain exploratory. The company is expanding research into oncology indications. The company strengthens its position through established microbiome expertise.
Vedanta Biosciences, Inc.
The company focuses on defined bacterial consortia. Demand is increasing as VE800 is being evaluated in immunotherapy combinations. Clinical uncertainty limits adoption. The company is advancing trials to validate efficacy. The company differentiates through precision microbiome design.
MaaT Pharma
The company targets microbiome restoration therapies. Demand is increasing as MaaT013 progresses in clinical trials. Regulatory uncertainty constrains commercialization timelines. The company is advancing late-stage trials. The company positions itself in microbiome immunotherapy enhancement.
Enterome
The company develops microbiome-derived immunotherapies. Demand is increasing as EO2401 explores immune activation mechanisms. Clinical validation remains limited. The company is expanding trial programs. The company focuses on microbiome-derived peptides.
4D Pharma plc
The company focuses on single-strain microbiome therapeutics. Demand is increasing as MRx0518 is tested in combination therapies. Financial constraints impact development pace. The company is partnering with oncology firms. The company leverages strain-specific mechanisms.
Finch Therapeutics Group, Inc.
The company develops microbiome restoration therapies. Demand is increasing as CP101 advances in development. Regulatory challenges limit progress. The company is refining clinical strategies. The company focuses on microbiome ecosystem restoration.
Kaleido Biosciences, Inc.
The company focuses on microbiome metabolic modulation. Demand is increasing as metabolic pathways are linked to immune response. Clinical progress remains limited. The company is exploring new applications. The company differentiates through metabolic targeting.
Key Developments
May 2026: Kanvas Biosciences, a full-stack spatial biology company, announced it has raised a $48 million Series A funding round co-led by existing investors DCVC and Lions Capital LLC.
January 2026: Osel Inc., a clinical-stage biopharma company pioneering live biotherapeutic products (LBPs), announced a clinical trial agreement with SWOG Cancer Research Network for a pivotal Phase 3 clinical trial of its lead oncology candidate, MO-03, in combination with standard immuno-oncology (IO) regimens for advanced and metastatic renal cell carcinoma (mRCC). This marks the first-ever pivotal trial of a microbiome-based oral therapy in oncology.
January 2026: MaaT Pharma, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced that the first patient has been randomized in the IMMUNOLIFE Phase 2 clinical trial, a randomized multicenter study evaluating the potential of an oral pooled fecal microbiotherapy (MaaT033) in combination with Regeneron’s Cemiplimab (CB) in enhancing disease control rate versus best investigator’s choice (BIC) in patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to PD-1/PD-L1 blockade following antibiotic (ATB) exposure and who present ATB-induced gut dysbiosis.
August 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announced that patient recruitment is complete in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients.
Strategic Insights and Future Market Outlook
The market is transitioning toward integrated oncology frameworks where microbiome modulation enhances treatment efficacy. Demand is increasing as clinical evidence strengthens the link between microbiome and cancer outcomes. Companies are focusing on combination therapies to validate clinical relevance. Healthcare systems are adapting to incorporate microbiome-based diagnostics and therapeutics. The market is evolving as microbiome science becomes embedded in oncology care.
Future growth depends on clinical validation and regulatory clarity. Demand is shifting as precision medicine expands to include microbiome profiling. Pharmaceutical companies are investing in research to address unmet needs in treatment resistance. Regulatory support is expected to improve as more therapies reach approval stages. The market is progressing toward broader clinical adoption as evidence accumulates.
The microbiome-oncology market is establishing itself as a critical adjunct to immunotherapy, where treatment success increasingly depends on microbial ecosystem modulation rather than solely targeting tumor biology.
Market Segmentation
By Geography
Key Countries Analysis
Regulatory & Policy Landscape
Table of Contents
1. EXECUTIVE SUMMARY
1.1 Market Overview
1.2 Scope of Microbiome-Oncology Market
1.3 Key Insights
1.4 Therapeutic Modality Snapshot (Microbiome-Based Interventions)
1.5 Market Outlook
2. DISEASE & EPIDEMIOLOGY ANALYSIS
2.1 Overview of Microbiome in Oncology
2.1.1 Role of Gut Microbiota in Cancer Development
2.1.2 Microbiome Influence on Immune Modulation
2.2 Cancer Types with Microbiome Association
2.2.1 Colorectal Cancer
2.2.2 Melanoma
2.2.3 Non-Small Cell Lung Cancer
2.2.4 Renal Cell Carcinoma
2.2.5 Hepatocellular Carcinoma
2.3 Epidemiology by Indication
2.3.1 Incidence and Prevalence of Microbiome-Linked Cancers
2.3.2 Microbiome Dysbiosis Trends in Oncology Patients
2.3.3 Mortality Trends
2.4 Biomarker and Microbiome Profiling
2.4.1 Microbial Signatures and Tumor Response
2.4.2 Antibiotic Exposure Impact
2.5 Patient Demographics
2.5.1 Age and Gender
2.5.2 Comorbidities
2.5.3 Geographic Variability in Microbiome Composition
3. MICROBIOME-ONCOLOGY MARKET DYNAMICS
3.1 Market Drivers
3.1.1 Increasing Evidence Linking Microbiome and Immunotherapy Response
3.1.2 Rising Adoption of Precision Medicine
3.1.3 Expansion of Immuno-Oncology Therapies
3.2 Market Restraints
3.2.1 Limited Clinical Validation of Microbiome Therapies
3.2.2 Regulatory Uncertainty for Live Biotherapeutics
3.3 Market Opportunities
3.3.1 Development of Microbiome-Based Adjuvant Therapies
3.3.2 Integration with Checkpoint Inhibitors
3.4 Market Challenges
3.4.1 Variability in Microbiome Composition
3.4.2 Standardization of Microbiome-Based Treatments
4. COMMERCIAL & MARKET ACCESS
4.1 Pricing Models for Biotherapeutics
4.2 Reimbursement Landscape
4.2.1 Public and Private Coverage
4.2.2 Value-Based Healthcare Models
4.3 Market Access Barriers
4.4 Clinical Adoption Challenges
5. INNOVATION & PIPELINE LANDSCAPE
5.1 Pipeline Overview
5.2 Pipeline by Development Phase
5.2.1 Phase I
5.2.2 Phase II
5.2.3 Phase III
5.3 Mechanism of Action (MoA)
5.3.1 Microbiome Modulation for Immune Activation
5.3.2 Enhancement of Checkpoint Inhibitor Response
5.3.3 Reduction of Treatment Toxicity
5.4 Modality Analysis
5.4.1 Live Biotherapeutic Products (LBPs)
5.4.2 Fecal Microbiota Transplantation (FMT)
5.4.3 Microbiome-Derived Small Molecules
5.5 Clinical Trial Landscape (ClinicalTrials.gov / EU CTR Verified)
6. TREATMENT LANDSCAPE
6.1 Current Standard Oncology Therapies
6.1.1 Immunotherapy
6.1.2 Targeted Therapy
6.1.3 Chemotherapy
6.2 Microbiome-Based Therapeutic Integration
6.2.1 Adjunctive Use with Checkpoint Inhibitors
6.2.2 Role in Enhancing Treatment Response
6.3 Approved Oncology Therapies Influenced by Microbiome
6.3.1 Pembrolizumab (Keytruda)
6.3.2 Nivolumab (Opdivo)
6.3.3 Atezolizumab (Tecentriq)
6.4 Emerging Treatment Strategies
6.4.1 Microbiome Restoration Therapies
6.4.2 Personalized Microbiome Modulation
7. MICROBIOME-ONCOLOGY MARKET SIZE & FORECAST
7.1 Historical Market Size Analysis
7.2 Forecast (2026–2035)
7.3 CAGR Analysis
7.4 Market Share by Therapy Type
8. MICROBIOME-ONCOLOGY MARKET SEGMENTATION
8.1 By Therapy Type
8.1.1 Microbiome-Based Therapeutics
8.1.2 Immunotherapy
8.1.3 Targeted Therapy
8.1.4 Chemotherapy
8.2 By Drug Class
8.2.1 Live Biotherapeutic Products
8.2.2 Immune Checkpoint Inhibitors
8.2.3 Microbiome Modulators
8.3 By Indication
8.3.1 Colorectal Cancer
8.3.2 Melanoma
8.3.3 Lung Cancer
8.3.4 Renal Cell Carcinoma
8.3.5 Liver Cancer
8.4 By Route of Administration
8.4.1 Oral
8.4.2 Intravenous
8.4.3 Rectal (FMT)
8.5 By End User
8.5.1 Hospitals
8.5.2 Cancer Research Institutes
8.5.3 Specialty Clinics
8.6 By Distribution Channel
8.6.1 Hospital Pharmacies
8.6.2 Specialty Pharmacies
9. GEOGRAPHICAL ANALYSIS (REGIONAL LEVEL)
9.1 North America
9.1.1 Market Size & Growth
9.1.2 Demand Drivers
9.1.3 Regulatory Overview
9.1.4 Competitive Intensity
9.2 Europe
9.2.1 Market Size & Growth
9.2.2 Demand Drivers
9.2.3 Regulatory Overview
9.2.4 Competitive Intensity
9.3 Asia-Pacific
9.3.1 Market Size & Growth
9.3.2 Demand Drivers
9.3.3 Regulatory Overview
9.3.4 Competitive Intensity
9.4 Latin America
9.4.1 Market Size & Growth
9.4.2 Demand Drivers
9.4.3 Regulatory Overview
9.4.4 Competitive Intensity
9.5 Middle East & Africa
9.5.1 Market Size & Growth
9.5.2 Demand Drivers
9.5.3 Regulatory Overview
9.5.4 Competitive Intensity
10. KEY COUNTRIES ANALYSIS
10.1 United States
10.1.1 Market Size
10.1.2 Epidemiology
10.1.3 Regulatory Framework (FDA)
10.1.4 Reimbursement
10.1.5 Key Companies and Pipeline Presence
10.2 Canada
10.2.1 Market Size
10.2.2 Epidemiology
10.2.3 Regulatory Framework
10.2.4 Reimbursement
10.2.5 Key Companies and Pipeline Presence
10.3 Germany
10.3.1 Market Size
10.3.2 Epidemiology
10.3.3 Regulatory Framework
10.3.4 Reimbursement
10.3.5 Key Companies and Pipeline Presence
10.4 United Kingdom
10.4.1 Market Size
10.4.2 Epidemiology
10.4.3 Regulatory Framework
10.4.4 Reimbursement
10.4.5 Key Companies and Pipeline Presence
10.5 France
10.5.1 Market Size
10.5.2 Epidemiology
10.5.3 Regulatory Framework
10.5.4 Reimbursement
10.5.5 Key Companies and Pipeline Presence
10.6 Italy
10.6.1 Market Size
10.6.2 Epidemiology
10.6.3 Regulatory Framework
10.6.4 Reimbursement
10.6.5 Key Companies and Pipeline Presence
10.7 Spain
10.7.1 Market Size
10.7.2 Epidemiology
10.7.3 Regulatory Framework
10.7.4 Reimbursement
10.7.5 Key Companies and Pipeline Presence
10.8 China
10.8.1 Market Size
10.8.2 Epidemiology
10.8.3 Regulatory Framework (NMPA)
10.8.4 Reimbursement
10.8.5 Key Companies and Pipeline Presence
10.9 Japan
10.9.1 Market Size
10.9.2 Epidemiology
10.9.3 Regulatory Framework (PMDA)
10.9.4 Reimbursement
10.9.5 Key Companies and Pipeline Presence
10.10 India
10.10.1 Market Size
10.10.2 Epidemiology
10.10.3 Regulatory Framework (CDSCO)
10.10.4 Reimbursement
10.10.5 Key Companies and Pipeline Presence
10.11 South Korea
10.11.1 Market Size
10.11.2 Epidemiology
10.11.3 Regulatory Framework
10.11.4 Reimbursement
10.11.5 Key Companies and Pipeline Presence
10.12 Australia
10.12.1 Market Size
10.12.2 Epidemiology
10.12.3 Regulatory Framework
10.12.4 Reimbursement
10.12.5 Key Companies and Pipeline Presence
10.13 Brazil
10.13.1 Market Size
10.13.2 Epidemiology
10.13.3 Regulatory Framework
10.13.4 Reimbursement
10.13.5 Key Companies and Pipeline Presence
10.14 Mexico
10.14.1 Market Size
10.14.2 Epidemiology
10.14.3 Regulatory Framework
10.14.4 Reimbursement
10.14.5 Key Companies and Pipeline Presence
10.15 Saudi Arabia
10.15.1 Market Size
10.15.2 Epidemiology
10.15.3 Regulatory Framework
10.15.4 Reimbursement
10.15.5 Key Companies and Pipeline Presence
10.16 South Africa
10.16.1 Market Size
10.16.2 Epidemiology
10.16.3 Regulatory Framework
10.16.4 Reimbursement
10.16.5 Key Companies and Pipeline Presence
11. REGULATORY & POLICY LANDSCAPE
11.1 United States (FDA – Live Biotherapeutic Products Guidance)
11.2 Europe (EMA – Advanced Therapy and Microbiome Regulation)
11.3 Japan (PMDA – Biologics and Microbiome Therapies)
11.4 India (CDSCO – Biologics and Emerging Therapies)
11.5 China (NMPA – Microbiome and Biologic Regulation)
12. COMPETITIVE LANDSCAPE
12.1 Market Structure and Emerging Players
12.2 Strategic Collaborations
12.3 Licensing and Partnerships
12.4 Investment Trends in Microbiome-Oncology
13. COMPANY PROFILES
13.1 Seres Therapeutics, Inc.
13.1.1 Approved Products
13.1.1.1 SER-109 (Vowst) – Fecal microbiota spores (FDA-approved for C. difficile infection)
13.1.2 Key Indications: Recurrent C. difficile infection (non-oncology)
13.1.3 Pipeline (Phase I/II/III – Oncology microbiome modulation trials)
13.2 Ferring Pharmaceuticals
13.2.1 Approved Products
13.2.1.1 RBX2660 (Rebyota) – Fecal microbiota suspension
13.2.2 Key Indications: Recurrent C. difficile infection
13.2.3 Pipeline (Microbiome applications in oncology)
13.3 Vedanta Biosciences, Inc.
13.3.1 Approved Products: None
13.3.2 Pipeline
13.3.2.1 VE800 (Phase I/II – Microbiome-based immunotherapy combination)
13.4 MaaT Pharma
13.4.1 Approved Products: None
13.4.2 Pipeline
13.4.2.1 MaaT013 (Phase II/III – Microbiome therapy in oncology)
13.5 Enterome
13.5.1 Approved Products: None
13.5.2 Pipeline
13.5.2.1 EO2401 (Phase I/II – Microbiome-derived immunotherapy)
13.6 4D Pharma plc
13.6.1 Approved Products: None
13.6.2 Pipeline
13.6.2.1 MRx0518 (Phase I/II – Microbiome therapy in solid tumors)
13.7 Finch Therapeutics Group, Inc.
13.7.1 Approved Products: None
13.7.2 Pipeline
13.7.2.1 CP101 (Microbiome therapeutic candidate)
13.8 Kaleido Biosciences, Inc.
13.8.1 Approved Products: None
13.8.2 Pipeline
13.8.2.1 KB295 (Microbiome metabolic modulator – clinical evaluation)
13.9 Locus Biosciences
13.9.1 Approved Products: None
13.9.2 Pipeline
13.9.2.1 LBPs targeting microbiome modulation (clinical stage)
13.10 Synthetic Biologics, Inc.
13.10.1 Approved Products: None
13.10.2 Pipeline
13.10.2.1 SYN-004 (Ribaxamase – microbiome protection approach)
14. FUTURE OUTLOOK
14.1 Role of Microbiome in Precision Oncology
14.2 Integration with Immunotherapy
14.3 Advances in Live Biotherapeutics
14.4 Long-Term Market Potential
15. METHODOLOGY
15.1 Data Sources
15.2 Primary Research
15.3 Secondary Research
15.4 Forecasting Approach
15.5 Assumptions and Limitations
Request Customization
Tell us your specific requirements and we will customize this report for you.
Download Free Sample
Get a sample copy of this report with charts, TOC, and methodology.
Speak to Analyst
Ask our analysts any questions you have about this market research report.
Microbiome-Oncology Market Report
Trusted by the world's leading organizations
